Abstract 232O
Background
Exercise is recognised as a supportive treatment for breast cancer, however evidence for its effects on long-term prognosis is scarce. Here we investigated the effects of two high-intensity exercise interventions on breast cancer survival and recurrence.
Methods
Between 2013-2016, 240 female breast cancer patients starting chemotherapy were randomised to either usual care (UC) or the 16-week Optitrain intervention; high-intensity interval training was combined with either resistance (RT-HIIT) or aerobic exercise (AT-HIIT). Outcomes were overall survival (OS), breast cancer-specific survival (BCSS), breast cancer-free interval (BCFI), distant recurrence-free interval (DRFI), and invasive breast cancer-free survival (IBCFS). Registry data was obtained from three National Swedish Registers until December 31, 2023. Intervention effects were described using Kaplan-Meier survival analysis, Cox proportional hazards models, and sensitivity analyses.
Results
Overall, 232 of the 240 women were identified in national registers. 19, 11, 19, 13, and 26 events were registered for the outcomes OS, BCSS, BCFI, DRFI, and IBCFS, respectively. Beneficial effects of the exercise interventions on breast cancer prognosis (log-rank testing) were found for OS and IBCFS. The RT-HIIT intervention significantly affected hazard ratios (HRs) for several outcomes, as shown in the Table. Table: 232O
| Group | Model | OS | BCSS | BCFI | DRFI | IBCFS |
| RT-HIIT | Crude | 0.18 (0.04, 0.83) | 0.18 (0.02, 1.58) | 0.21 (0.05, 0.96) | 0.14 (0.02, 1.10) | 0.22 (0.06, 0.76) |
| AT-HIIT | 0.67 (0.25, 1.76) | 0.97 (0.28, 3.34) | 0.85 (0.33, 2.21) | 0.69 (0.22, 2.17) | 0.74 (0.32, 1.68) | |
| UC | 1.00 (Ref.) | 1.00 (Ref.) | 1.00 (Ref.) | 1.00 (Ref.) | 1.00 (Ref.) | |
| RT-HIIT | Adjusted Age, menopausal status, BMI, tumour characteristics, and chemo-therapy regimen. | 0.26 (0.05, 1.31) | 0.24 (0.02, 2.34) | 0.14 (0.02, 1.24) | 0.17 (0.02, 1.60) | 0.19 (0.04, 0.90) |
| AT-HIIT | 0.84 (0.26, 2.69) | 1.06 (0.22, 5.08) | 1.21 (0.36, 4.00) | 0.99 (0.25, 3.87) | 0.98 (0.36, 2.63) | |
| UC | 1.00 (Ref.) | 1.00 (Ref.) | 1.00 (Ref.) | 1.00 (Ref.) | 1.00 (Ref.) |
Conclusions
This investigation suggests beneficial effects of the Optitrain intervention on breast cancer prognosis, supporting exercise as a cornerstone of supportive care during chemotherapy treatment for breast cancer.
Clinical trial identification
NCT02522260.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The Swedish Cancer Society (130452) and The Swedish Society for Medical Research.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
LBA12 - eMouvoir: Randomised phase III trial evaluating the impact of a personalized and remote physical activity (PA) for breast cancer survivors (BCS). Results on the quality of life (QoL)
Presenter: Laurence Vanlemmens
Session: Proffered paper session: Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA12 and 232O
Presenter: Jennifer Ligibel
Session: Proffered paper session: Breast cancer, early stage
Resources:
Slides
Webcast
Q&A
Session: Proffered paper session: Breast cancer, early stage
Resources:
Webcast
LBA10 - Primary endpoint results of the Neo-CheckRay phase II trial evaluating stereotactic body radiation therapy (SBRT) +/- durvalumab (durva) +/- oleclumab (ole) combined with neo-adjuvant chemotherapy (NACT) for early-stage, high risk ER+/HER2- breast cancer (BC)
Presenter: Alex De Caluwe
Session: Proffered paper session: Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
LBA11 - Neoadjuvant nivolumab/relatlimab or nivolumab/ipilimumab in triple negative breast cancer with high tumor-infiltrating lymphocytes (TILs)
Presenter: Iris Nederlof
Session: Proffered paper session: Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
LBA13 - Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (Pts) with HR+/HER2− early breast cancer (EBC): 4-year outcomes from the NATALEE trial
Presenter: Peter A. Fasching
Session: Proffered paper session: Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA10, LBA11 and LBA13
Presenter: Elgene Lim
Session: Proffered paper session: Breast cancer, early stage
Resources:
Slides
Webcast
Q&A
Session: Proffered paper session: Breast cancer, early stage
Resources:
Webcast